Curis Inc. (CRIS) Stock News
Follow the latest Curis Inc. (CRIS) news and market headlines alongside the live CRIS price. Stay informed on what's moving CRIS.
Curis (CRIS)
NASDAQ
$0.45
$0.13(-22.35%)
Market Closed
News
- Read Full ArticleBenzinga
- BenzingaRead Full Article
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $6
HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $43 to $6.
- MassiveRead Full Article
Curis (CRIS) Q3 2026 Earnings Call Transcript
Curis reported Q3 2026 results highlighting progress on its lead oncology program emavusertib. The company announced an 86% response rate in BTK-naive patients with PCNSL (compared to 39-67% for BTK inhibitor monotherapy alone) and a 26% response rate in salvage-line patients. A CLL study was initiated with 12 patients enrolled across 11 sites, with initial data expected by year-end. The company reported a net loss of $8.1 million for Q3 2026 and $5 million in cash, with runway into 2027. Full enrollment in the PCNSL registrational study is expected by end of 2027, with NDA filing anticipated in 2028.
- Read Full ArticleBenzinga
- Read Full ArticleBenzinga
- BenzingaRead Full Article
Curis Q3 EPS $(1.94) Beats $(2.01) Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(1.94) per share which beat the analyst consensus estimate of $(2.01) by 3.48 percent. This is a 80.2 percent increase over losses of $(9.80) per share from the same
Explore More US Stocks
Largest Market Cap
See US stocks with the highest market capitalization
Most Actively Traded
Discover today's most actively traded US stocks
Top Gainers
Browse today's leading gainers in the US stock market
Top 5 Cryptocurrencies
Explore the cryptocurrencies with the highest market capitalization
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CRIS, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.